Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
News
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/d5/0f/11/d50f110c-13c9-ef8a-ce1b-aa572924cd22/mza_3951954547589852292.jpg/600x600bb.jpg
LifeLines by Biocom California
Biocom California
10 episodes
2 days ago
Candid one-on-one conversations with life science leaders in California and beyond.
Show more...
Life Sciences
Science
RSS
All content for LifeLines by Biocom California is the property of Biocom California and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Candid one-on-one conversations with life science leaders in California and beyond.
Show more...
Life Sciences
Science
https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/37201488/37201488-1680647568656-fb187a50e4e87.jpg
Episode 3: Daré Bioscience is Advocating For Equity in Women’s Health and Building a Pipeline of Differentiated Treatment Options 
LifeLines by Biocom California
29 minutes 47 seconds
2 years ago
Episode 3: Daré Bioscience is Advocating For Equity in Women’s Health and Building a Pipeline of Differentiated Treatment Options 

Women make up half of the globe’s population, but the dollars devoted to finding treatments for women’s unique health issues—beyond conditions such as breast cancer—are significantly underfunded. Only 1 percent of research dollars are invested in women's health concerns, and women's health represents only 2 percent of the development pipeline of preclinical products for non-cancer related conditions, according to a 2022 McKinsey & Company report. Sabrina Martucci Johnson, president and CEO of Daré Bioscience, says this is not congruent, at all, with the need and demand for such products and the fact that women account for 80 percent of consumer purchase decisions for healthcare.  

“A lot of the women's health indications are conditions that are simply just a part of being a woman. They're not life threatening, but they're life altering in many cases,” Sabrina says. This gender gap in product development motivated Sabrina to found Daré Bioscience (pronounced Dah-ray and meaning "to give" in Italian) in 2015, which is focused on finding novel treatments for women’s health issues—encompassing reproductive, vaginal, and sexual health—and bringing them to market.

In this episode of LifeLines—airing just before National Women’s Health Week—we delve more into these healthcare inequities and learn about how Daré is addressing these unmet health needs with its product pipeline. The company’s first FDA-approved product, Xaciato, came out in 2021, and Daré is in its Phase 3 clinical trial for a monthly hormone-free contraceptive, in collaboration with Bayer—the only company that's built an over billion-dollar contraceptive brand. It’s also in Phase 2 for its product Sildenafil, a treatment for female sexual arousal disorder.  

Sabrina shares the challenges of raising capital when you're one of the first in your field, despite having proof of concept, and how three mentors (and a chance encounter on an elevator) were instrumental in launching Daré. You can follow Sabrina Martucci Johnson and Daré Bioscience on LinkedIn. 

LifeLines is produced by Biocom California, the leader and advocate for life science in California and beyond. To learn more about us, visit ⁠biocom.org⁠ or engage with us on ⁠Twitter⁠ and ⁠LinkedIn⁠. For a transcript of this episode, you can download it ⁠here.⁠ Interested in becoming a member or joining us on this podcast? Email ⁠podcast@biocom.org⁠. 


Host: Chris Conner

Executive Producer: Marie Tutko

Senior Producer: Vincenzo Tarantino

Associate Producer: Lauren Panetta

Program & Research Coordinator: Katy Burgess

Transcripts By: Jessica Schneider

Senior Director of Marketing: Heather Ramsay

Graphic Design By: Raquel Papike

LifeLines by Biocom California
Candid one-on-one conversations with life science leaders in California and beyond.